Pfizer said a late-stage study of its sasanlimab drug candidate met its key goal in certain patients ... high-risk non-muscle invasive bladder cancer met its primary endpoint of event-free survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback